According to MRFR analysis, the global biopharmaceutical
excipients market size is expected to register a CAGR of~6.8% from 2021 to
2027 and is expected to hold a value of ~USD 3,114.6 million by 2027
The global biopharmaceutical excipients market is driven by
several factors, such as increasing demand for oral formulations across the
globe, rising demand for customized medicines, and an increasing geriatric
population. Other factors such as increasing patients with chronic
ailmentscoupled with growing life expectancy are driving the production of
biopharmaceuticals. In addition, increasing stress, back pains, body aches, and
headaches has augmented the demand for topical type formulation, accelerating
the market growth.
The industry players focus on expanding their global
footprint by strategic partnerships, investing in some company’s stock,
acquisitions, and product launches. For instance, in February 2020, ReForm
Biologics (US) partnered with MilliporeSigma (US) to commercialize excipients
used in biotherapeutics. In August 2019, LBB Specialties (US) announced the
strategic partnership with MEGGLE (Germany)to expand its excipient distribution
channel across the US. In December 2018, Roquette (France) bought a majority
stake in excipient producer Crest Cellose (India) that enabled the company to
expand its product portfolio and presence in the Indian generic pharmaceutical
market. Furthermore, the prominent players focus on new developments, employee
satisfaction, the transformation of their research wings, and expanding their
distribution network. These factors will augment the market growth and will
increase theproduct demand in the forecast timeline.
Key Players
Some of the key players in the global biopharmaceutical
excipients market are Merck KGaA (Germany), Colorcon (BPSI Holdings Inc) (US),
BASF SE(Germany), Associated British Foods plc (UK), Signet Excipients Pvt. Ltd
(IMCD) (Netherlands), Sigachi Industries Limited (Hyderabad), Spectrum Chemical
Manufacturing Corp. (US), Roquette Frères (France), Clariant (Switzerland), DFE
Pharma (Germany), J. Rettenmaier & Söhne Gmbh + Co Kg (Germany), and Evonik
Industries AG (Germany).
Segmentation
The global biopharmaceutical
excipients market outlook is categorized into product and formulation. Based
on the product category, the market has been segregated into solubilizers &
surfactants/emulsifiers, polyols and carbohydrates, and specialty excipients.
The carbohydrates segment is expected to hold a considerable share of the
market in 2021. Increasing R&D activities for the development of lipid and
protein excipient-based corona vaccines is fueling the market demand. In
addition, the high demand for carbohydrate-based medicines for the infant
segment is propelling the biopharmaceutical excipient market.
Based on formulation, the global biopharmaceutical
excipients market has been classified as oral, topical, and injectables. The
oral segmentheld the major share in 2020 due to the easy intake procedure and
availability of oral medicines throughout the hospitals and retail stores.
Additionally, the demand for oral and topical formulations is accelerating due
to the growing preference for on-the-go treatment and ambulatory treatment
services coupled with increasing cases of trypanophobia.
Regional Analysis
North America is projected to dominate the biopharmaceutical
excipients market due to the growing adoption of the latest drug manufacturing
technologies, increasing chronic diseases, and expansion of production
capabilities of the industry players across the region. In addition,
highinvestments were made in the development of new excipient variants to
advance the product portfolio. Furthermore, the key players are involved in
collaborations, mergers, and R&D activities that propel market growth.
Europe embraces the second-largest position in the
biopharmaceutical excipients market due to growing investments in the
pharmaceutical sector and increasing production capacity across the region. In
addition, the region experienced high demands for pharmaceutical products.
Moreover, countries such asGermany, Italy, the UK, France, and Spain have
invested huge amounts in the manufacturing of new vaccines.
Asia-Pacific is anticipated to be the fastest-growing
regional market over the projected timeline due to the rising investment in
pharmaceutical research and production facilities, increasing consumption of
medicines, and supportive government alliances and subsidy schemes. In
addition, the availability of highly skilled research employees and an
economical workforce is creating opportunities for the industry players.
About US:
Market Research Future (MRFR), enable customers to unravel the complexity
of various industries through Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research
(CFR), and Market Research & Consulting Services.
The Wall